In the high-stakes world of biopharmaceutical manufacturing, the transition of a product from the laboratory bench to large-scale commercial production is often considered a purely technical milestone. However, beneath the rigid framework of Standard Operating Procedures (SOPs) and Good Manufacturing Practice (GMP) documentation lies a hidden, fragile asset: tacit knowledge.
As the biopharmaceutical industry increasingly leans on Contract Development and Manufacturing Organizations (CDMOs) to scale complex therapies, a significant portion of the “know-how” that makes these processes successful is being lost. This erosion of institutional wisdom is not merely an operational nuisance; it is a systemic threat to product quality, patient safety, and corporate valuation.
The Anatomy of the Tech Transfer Gap
Technology transfer serves as the bridge between R&D, pilot plants, and commercial manufacturing sites. While organizations meticulously document the "what" and "how" of a process, they often fail to capture the "why"—the nuances, the failed experiments, and the subtle sensory cues that experienced researchers rely on to navigate complex biological systems.
With over 86% of biopharma companies now outsourcing at least a portion of their manufacturing activities, the frequency of technology transfer has surged. Ryan Chen, director of Product Marketing at ValGenesis, emphasizes that this is not a one-time event. “Technology transfer occurs repeatedly across the lifecycle: from CMC (Chemistry, Manufacturing, and Controls) development to first GMP clinical supply, and further down to commercial scale, between manufacturing sites and even post-approval when capacity, network, or process changes are required,” Chen explains.
Every time a process shifts from one environment to another, there is a risk of knowledge degradation. When that transfer involves a handover to an external CDMO, the organizational silos can widen the gap, leaving the receiving site with a manual but without the mentor.
A Chronology of Knowledge Erosion
The current crisis is the result of three converging historical trends that have reached a boiling point in the mid-2020s.
1. The Retirement Wave (2020–Present)
The "Silver Tsunami" is real. With approximately 11,000 baby boomers reaching retirement age every day in the United States, the biopharma industry is witnessing a mass exodus of veteran scientists and engineers. These individuals carry decades of "tribal knowledge"—the kind of expertise that isn’t written in a patent or a batch record but is stored in the intuition developed through years of troubleshooting. When they retire, that knowledge leaves the building.
2. The Outsourcing Acceleration (2022–2024)
As biopharma firms sought to mitigate supply chain risks following the global pandemic, outsourcing became the default strategy for rapid clinical supply. This accelerated the volume of tech transfers, often forcing projects through at a pace that precluded the thorough knowledge-sharing sessions required to move beyond simple documentation.
3. The 2025 Downsizing Cycle
Following a period of aggressive expansion, the industry faced a cooling-off period in 2025, with biopharma layoffs rising by 16%. Manufacturing and CDMO operational roles were among the hardest hit. When a company slashes headcount, the first thing to disappear is the "excess" time required to mentor new hires or document institutional learning, further thinning the knowledge base.
The Financial and Regulatory Implications
The loss of tacit knowledge carries a heavy price tag. Merck has previously reported $125 million in value attributable specifically to rigorous knowledge management over a decade. Conversely, poor tech transfer leads to batch failures, regulatory delays, and the need for costly comparability studies—all of which erode the bottom line.
Regulatory bodies have recognized the danger. The Parenteral Drug Association (PDA) Technical Report No. 65 explicitly recommends the capture of tacit knowledge as a best practice. However, the industry remains trapped in a document-centric mindset. Because no regulatory framework mandates a specific methodology for capturing "intuition," companies often default to the bare minimum of compliance.
The ISPE Good Practice Guide on Knowledge Management notes that tacit knowledge is "arguably underappreciated" in the pharmaceutical industry. The reason is structural: the industry is built on verification and audit trails. If it isn’t written down, it didn’t happen—but in the world of biologics, the most important things are often what happens between the steps.
The Academic-to-Industry Divide
The most profound loss of knowledge often occurs at the very beginning: the transfer of intellectual property from academic labs to commercial entities.
"Academic to industry packages are often associated with immature processes and undocumented tacit knowledge," says Chen. In an academic setting, the priority is discovery. Processes are small-scale, exploratory, and intentionally flexible to foster creativity. There is little incentive to create a scalable, GMP-compliant workflow.
When a drug candidate is licensed out, the industry partner inherits the patents and the publications. They receive the data on what the product does, but they rarely receive the "lab notebook in the head" of the principal investigator. They do not inherit the knowledge of the fifty failed runs that led to the one successful experiment. When that researcher moves to a new project or a new institution, that entire history of "what doesn’t work" is lost, forcing the industry to reinvent the wheel.
Advanced Modalities: The High-Stakes Complexity
If small-molecule drug manufacturing is a recipe, cell and gene therapy (CGT) manufacturing is a performance art. The rise of advanced modalities has fundamentally changed the stakes of technology transfer.
"Advanced modalities such as cell and gene therapies introduce greater biological variability, complex potency assays, aseptic processing requirements, and sensitivity to operator technique," Chen notes.
In CAR-T manufacturing, the human element is non-negotiable. Steps like cell isolation, expansion, and harvesting are highly manual. A slight variation in the angle of a pipette or the duration of an incubation period can significantly impact the yield and quality of the final therapy. Because living cells cannot be terminally sterilized, the process itself must be flawless.
When this process is transferred to a CDMO, the "operator technique" becomes a variable that standard documentation often fails to cover. If the CDMO’s staff does not understand the biological reasoning behind a specific handling technique, they cannot effectively replicate the process, leading to higher rates of contamination and variability.
Strategies for Institutional Resilience
To mitigate these risks, industry leaders must shift their perspective on technology transfer. It should not be viewed as a late-stage operational handoff, but as an integrated knowledge-management strategy that begins at the R&D stage.
1. Design for Transfer
Founders and R&D leads must design processes with the end in mind. This means standardizing workflows, even in the lab, and utilizing digital tools that can capture decision-making logs, not just final data points.
2. Institutionalize Knowledge Management
Knowledge management must be moved from the "nice-to-have" category to a core QMS (Quality Management System) function. Companies should implement "Knowledge Capture Sessions" as part of every tech transfer milestone, where outgoing and incoming teams engage in direct, facilitated dialogue.
3. Invest in Analytical Readiness
Because biological processes are complex, companies must invest heavily in analytical tools that can monitor the process in real-time. By relying on robust, data-driven analytical measures, firms can reduce their dependence on operator "feel" and replace it with objective, actionable metrics.
4. Selecting Partners with Modality Expertise
The era of the "generalist" CDMO is coming to an end for advanced therapies. Companies must select partners that possess deep, specific expertise in the modality being produced. Governance and change-control discipline should be embedded from the very first engagement, rather than treated as an afterthought during the final stage of tech transfer.
Conclusion
The loss of tacit knowledge is a quiet, steady drain on the biopharmaceutical industry’s capacity to innovate and deliver life-saving therapies. As the complexity of products grows and the workforce continues to shift, the industry must evolve. Moving beyond the "document-centric" culture to one that prioritizes the active management of expertise will not only save millions in avoidable errors but will ultimately ensure that the next generation of therapies reaches patients safely and efficiently. Technology transfer is not just about moving data—it is about moving the intelligence required to build the future of medicine.
About the Author
